Nintedanib, an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-3, and PDGFR, is approved for the treatment of idiopathic pulmonary fibrosis and lung cancer [56,57,58]. Here, PDGFRB is linked to lung cancer.